Analysts Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Target Price at $8.50

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has received an average recommendation of “Buy” from the ten ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $8.50.

AQST has been the subject of several recent research reports. Wall Street Zen cut Aquestive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Wednesday, January 21st. Piper Sandler raised their target price on Aquestive Therapeutics from $5.00 to $8.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, Lake Street Capital set a $6.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, February 3rd.

Institutional Trading of Aquestive Therapeutics

Several hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. increased its holdings in Aquestive Therapeutics by 17.0% in the 3rd quarter. Victory Capital Management Inc. now owns 12,794 shares of the company’s stock valued at $72,000 after purchasing an additional 1,862 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Aquestive Therapeutics by 6.0% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock worth $156,000 after purchasing an additional 2,649 shares in the last quarter. Informed Momentum Co LLC boosted its position in shares of Aquestive Therapeutics by 1.8% during the fourth quarter. Informed Momentum Co LLC now owns 155,053 shares of the company’s stock worth $1,002,000 after buying an additional 2,721 shares during the period. Stifel Financial Corp grew its stake in shares of Aquestive Therapeutics by 0.9% in the fourth quarter. Stifel Financial Corp now owns 369,728 shares of the company’s stock valued at $2,388,000 after buying an additional 3,300 shares in the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of Aquestive Therapeutics by 6.8% in the fourth quarter. AQR Capital Management LLC now owns 61,709 shares of the company’s stock valued at $399,000 after buying an additional 3,934 shares in the last quarter. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Trading Down 0.3%

AQST stock opened at $3.95 on Thursday. The firm has a 50-day moving average of $4.56 and a two-hundred day moving average of $5.19. Aquestive Therapeutics has a 12 month low of $2.12 and a 12 month high of $7.55. The company has a market cap of $481.90 million, a price-to-earnings ratio of -5.56 and a beta of 1.65.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.